Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers

被引：4
|
作者：
Zhang, Dongling [1 ,2 ,3 ]
Zhou, Liche [4 ]
Shi, Yuting [5 ]
Liu, Jun
Wei, Hongjiang [5 ]
Tong, Qiqi [6 ]
He, Hongjian [7 ]
Wu, Tao [1 ,2 ,3 ]
机构：
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Ctr Movement Disorders, Beijing, Peoples R China
[2] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Inst Brain Disorders, Parkinsons Dis Ctr, Beijing, Peoples R China
[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Neurol & Inst Neurol, Sch Med, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Inst Med Imaging Technol, Sch Biomed Engn, Shanghai, Peoples R China
[6] Zhejiang Lab, Res Ctr Healthcare Data Sci, Hangzhou, Zhejiang, Peoples R China
[7] Zhejiang Univ, Coll Biomed Engn & Instrument Sci, Ctr Brain Imaging Sci & Technol, Hangzhou, Zhejiang, Peoples R China
来源：
MOVEMENT DISORDERS | 2023年 / 38卷 / 01期
基金：
国家重点研发计划; 美国国家卫生研究院; 中国国家自然科学基金;
关键词：
leucine-rich repeat kinase 2; free water; biomarker; posterior substantia nigra; PARKINSONS-DISEASE; MULTISITE; ELIMINATION; BRAIN;
D O I：
10.1002/mds.29253
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Background: The alteration of substantia nigra (SN) degeneration in populations at risk of Parkinson's disease (PD) is unclear. Objective: We investigated free water (FW) values in the posterior SN (pSN) in asymptomatic LRRK2 G2019S mutation carriers. Methods: We analyzed diffusion imaging data from 28 asymptomatic LRRK2 G2019S mutation carriers and 30 healthy controls (HCs), whereas 11 asymptomatic LRRK2 G2019S carriers and 11 HCs were followed up. FW values in the pSN were measured and compared between the groups. The relationship between longitudinal changes in FW in the pSN and dopamine transporter striatal binding ratio (SBR) was analyzed. Results: FW values in the pSN were significantly elevated and kept increasing during follow-up in asymptomatic LRRK2 G2019S carriers. There was a negative correlation between FW changes in the left pSN and SBR changes in the left putamen. Conclusion: FW in the pSN has the potential to be a progression imaging marker of early dopaminergic degeneration in the population at risk of PD. (c) 2022 International Parkinson and Movement Disorder Society.
引用
收藏
页码：138 / 142
页数：5
相关论文
共 50 条
  • [21] The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation
    Hassin-Baer, Sharon
    Laitman, Yael
    Azizi, Esther
    Molchadski, Irena
    Galore-Haskel, Gilli
    Barak, Frida
    Cohen, Oren S.
    Friedman, Eitan
    JOURNAL OF NEUROLOGY, 2009, 256 (03) : 483 - 487
  • [22] LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase
    Choi, Insup
    Kim, Beomsue
    Byun, Ji-Won
    Baik, Sung Hoon
    Huh, Hyun
    Kim, Jong-Hyeon
    Mook-Jung, Inhee
    Song, Woo Keun
    Shin, Joo-Ho
    Seo, Hyemyung
    Suh, Young Ho
    Jou, Ilo
    Park, Sang Myun
    Kang, Ho Chul
    Joe, Eun-Hye
    NATURE COMMUNICATIONS, 2015, 6
  • [23] A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype
    Pirkevi, C.
    Lesage, S.
    Condroyer, C.
    Tomiyama, H.
    Hattori, N.
    Ertan, S.
    Brice, A.
    Basak, A. N.
    NEUROGENETICS, 2009, 10 (03) : 271 - 273
  • [24] Fall Risk and Gait in Parkinson's Disease: The Role of the LRRK2 G2019S Mutation
    Mirelman, Anat
    Heman, Talia
    Yasinovsky, Kira
    Thaler, Avner
    Gurevich, Tanya
    Marder, Karen
    Bressman, Susan
    Bar-Shira, Anat
    Orr-Urtreger, Avi
    Giladi, Nir
    Hausdorff, Jeffrey M.
    MOVEMENT DISORDERS, 2013, 28 (12) : 1683 - 1690
  • [25] Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development
    Alcalay, Roy N.
    Hsieh, Frank
    Tengstrand, Elizabeth
    Padmanabhan, Shalini
    Baptista, Marco
    Kehoe, Caitlin
    Narayan, Sushma
    Boehme, Amelia K.
    Merchant, Kalpana
    MOVEMENT DISORDERS, 2020, 35 (01) : 134 - 141
  • [26] A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype
    C. Pirkevi
    S. Lesage
    C. Condroyer
    H. Tomiyama
    N. Hattori
    S. Ertan
    A. Brice
    A. N. Başak
    neurogenetics, 2009, 10 : 271 - 273
  • [27] Clinical Expression of LRRK2 G2019S Mutations in the Elderly
    San Luciano, Marta
    Lipton, Richard B.
    Wang, Cuiling
    Katz, Mindy
    Zimmerman, Molly E.
    Sanders, Amy E.
    Ozelius, Laurie J.
    Bressman, Susan B.
    Saunders-Pullman, Rachel
    MOVEMENT DISORDERS, 2010, 25 (15) : 2571 - 2576
  • [28] Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease
    Fung, Hon-Chung
    Chen, Chiung-Mei
    Hardy, John
    Hernandez, Dena
    Singleton, Andrew
    Wu, Yih-Ru
    MOVEMENT DISORDERS, 2006, 21 (06) : 880 - 881
  • [29] Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson's disease
    du Toit, Nicola
    van Coller, Riaan
    Anderson, David G.
    Carr, Jonathan
    Bardien, Soraya
    NEUROGENETICS, 2019, 20 (04) : 215 - 218
  • [30] Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review
    Guedes, L. Correia
    Ferreira, J. J.
    Rosa, M. M.
    Coelho, M.
    Bonifati, V.
    Sampaio, C.
    PARKINSONISM & RELATED DISORDERS, 2010, 16 (04) : 237 - 242
12345